FINANCE/FUNDING ARTICLES

  • Is China’s Golden Era Ending?
    Is China’s Golden Era Ending?

    The value of China’s biotechs fell some 30 percent since the trade war began, and VC funding, while strong, slipped before that. Interest in China, however, remains strong.

  • How Biopharma & Medtech CFOs Are Viewing U.S. Tax Reform
    How Biopharma & Medtech CFOs Are Viewing U.S. Tax Reform

    Biopharma and medtech companies are expecting mostly positive results from the new Tax Cuts and Jobs Act (TCJA), according to research by The Deloitte Center for Health Solutions and Forbes Insights.

  • How To Put A Price Tag On Emerging Therapies
    How To Put A Price Tag On Emerging Therapies

    There’s no doubt that partnerships and M&As are key growth drivers in the biopharma industry.  But for collaborative relationships to occur, understanding the value of a company’s underlying assets is critical.

  • Serendipity: When Funders Found A Company
    Serendipity: When Funders Found A Company

    Foghorn Therapeutics is managing to sidestep some of the growing pains common to early companies, thanks to its genesis as a VC-founded company.

  • When Should Tax Functions Be Brought In-House?
    When Should Tax Functions Be Brought In-House?

    At what stage of a biopharma’s growth does it makes sense to bring on an internal tax function? The answer, of course, varies significantly, but here are some factors to consider when making this important business decision.

  • Recent Changes May Reshape Financial Reporting In The Life Sciences Industry
    Recent Changes May Reshape Financial Reporting In The Life Sciences Industry

    Changes to the accounting standards that affect matters like revenue recognition, the definition of a business, and leases could significantly affect the accounting for certain transactions in the life sciences industry.

  • Biopharma Startups Take Advantage Of Open IPO Window
    Biopharma Startups Take Advantage Of Open IPO Window

    Biopharma startups are enjoying a window of opportunity for successful IPOs that opened in mid-2017. CEOs share their experiences of going public, what is fueling IPOs, and tips for others thinking about making this important next step.

  • How Biotechs Can Avoid The Common Pitfalls Of Going Public
    How Biotechs Can Avoid The Common Pitfalls Of Going Public

    Many private biotech companies have either initiated the process of going public or are at least contemplating it. But they should be aware of very significant pitfalls that lie in wait, regardless of how they approach the offering.

  • Crowdfunding Fizzles As VC Soars
    Crowdfunding Fizzles As VC Soars

    When the economy crashed a few years ago, crowdfunding offered startups a possible lifeline. But it arrived too late to be much use. Now that money is flooding back into biotech, companies needn’t clutter cap sheets with scores of non-accredited investors, so equity crowdfunding is nearly a nonstarter.

  • How To Survive The Perilous Life Sciences Startup Climb
    How To Survive The Perilous Life Sciences Startup Climb

    According to Noubar Afeyan, founder and CEO of Flagship Pioneering, his company shouldn’t be pigeonholed as a VC firm. ““From day one, our intent was to innovate and create new companies.” 

More finance/funding articles